To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

NCT05388695 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

19 and 22+ B Cell Hematologic Tumors
19 and 20+ B Cell Hematologic Tumors

Interventions

BIOLOGICAL: Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells

Sponsor

Hebei Senlang Biotechnology Inc., Ltd.

Collaborators

[object Object]